Worth

Episode Summary

Executive Summary: This RadioLab episode examines how society assigns monetary value to seemingly priceless things: life, death, and nature. It contrasts controversial drug pricing in oncology and hepatitis C with wartime condolence payments and ecosystem valuation, asking whether money can guide fair decisions or whether it reduces morally complex realities to flawed arithmetic.

Main Topics: Cancer drug pricing and the value of life (Priority: 5/5): The show opens with Zaltrap, a costly cancer drug offering only 42 extra days of life on average, prompting Memorial Sloan Kettering to boycott it and publicly challenge pharmaceutical pricing. Hepatitis C treatment and rationing cures (Priority: 5/5): Sovaldi is presented as a highly effective but expensive cure—$1,000 a pill, $84,000 total—forcing states and insurers to limit access despite its 95% cure rate. How much a year of life is worth (Priority: 4/5): The episode explores social and ethical attempts to price health gains, including the WHO guideline of 1–3x GDP per capita, and interviews ordinary people about what they’d pay for an extra year. Compensation for wartime civilian deaths (Priority: 5/5): A drone strike on a Yemeni wedding leads into a history of U.S. condolence payments, from Pershing’s World War I claims system to modern military payments under 'money as a weapon system.' Nature’s economic value (Priority: 5/5): The show shifts to ecosystem services, valuing bats, salt marshes, mangroves, and bees in dollar terms to show how nature provides hidden economic benefits. The limits and risks of monetizing everything (Priority: 4/5): Experts argue that pricing can help decision-making and conservation, but also risks reducing moral, aesthetic, and irreversible losses to simplistic market logic.

Key Arguments: Some cancer drugs are priced far beyond their marginal benefit, making public challenge and refusal of use a legitimate response. Drug prices matter not only because of sticker shock but because insurance pools mean one patient’s costly treatment affects everyone’s premiums and coverage. A cure can still be unaffordable if the system cannot absorb the upfront cost, especially when many patients need it at once. War compensation has evolved from a practical tool for maintaining control and legitimacy into a strategy for winning hearts and minds. Dollar amounts can function as a shared language of apology or amends, but they do not truly replace loss. Valuing ecosystems economically can protect them in policy debates, especially where non-economic arguments fail. However, monetizing nature can also encourage seeing ecosystems as replaceable assets, even when damage is irreversible. The 'bee story' shows that economic efficiency can temporarily make humans seem more valuable than natural systems, but those valuations can reverse quickly and unpredictably.

Data Points: Zaltrap survival benefit: 1.4 months (42 days) - Average added survival in the colon cancer drug discussed by Leonard Saltz Zaltrap cost: $30,000 for a 3-month course - Price of the drug after FDA approval Zaltrap monthly cost: $11,000/month - Stated as the monthly expense for the cancer drug Zaltrap price reduction: 50% discount - Sanofi cut the drug’s price after public criticism Medicare out-of-pocket estimate: About $2,200 per month - Estimated patient cost without supplemental insurance Sovaldi cure rate: 95% - Effectiveness of the hepatitis C drug in the first half of 2014 Sovaldi price per pill: $1,000 - Cost of one pill of the hepatitis C treatment Sovaldi total course cost: $84,000 - 12-week treatment total People treated with Sovaldi: 70,000 - U.S. patients treated in the first half of 2014 Estimated total Sovaldi spending: $5.88 billion - Rough multiplication of 70,000 treatments at $84,000 each WHO value-of-life guideline: 1–3x GDP per capita - Rule of thumb for spending on one more good year of life U.S. WHO-based threshold: $50,000–$150,000 - Approximate U.S. range implied by the WHO guideline Military condolence payment: $2,500 - Common payment cited in Iraq/Afghanistan claims files Property damage payment: $1,500 then $2,500 - Early military compensation ceilings, later raised 9/11 compensation range: $250,000 to just under $7 million - Federal compensation for families of those killed on September 11th Bat contribution to cotton farms: About $700,000 - Estimated share of farm revenue attributable to bats Annual farm revenue: $4–5 million - Collective value of cotton farms in the Texas example Global ecosystem services value: $142.7 trillion per year - Costanza’s estimate of worldwide ecosystem services Salt marsh pollution control value: $31.22 per hectare per year - Estimated flood/water/pollution control service value in New England Salt marsh food value: $338 per acre annually - Value tied to plants feeding fish that end up in the food chain Salt marsh birdwatching/local economy value: $90 per hectare - Additional economic contribution from recreation Wild bee pollination value: $190 billion - Estimated global value of pollination from wild bees Hand pollination effect: 30% higher fruit production - Reported increase in apple output in Mao County after human pollination

Pivotal Quotes: "What is one more year or one more month or one more day of life worth to us?" — Leonard Saltz: Core question raised during the cancer drug pricing discussion "Money as a weapon system" — Rich Gross: Military doctrine framing condolence payments in Iraq and Afghanistan "the pool of imagination and creativity from which we as humans are able to draw" — J.B. McKinnon: His argument for valuing biodiversity beyond direct economics

Implications: Listeners are left with a tension: pricing can expose hidden costs and shape policy, but it can also distort moral judgment. Future healthcare, military, and environmental decisions may increasingly rely on monetary valuation—even as some losses remain impossible to truly price.